Kayata Hiroyuki, Isaka Mitsuhiro, Terada Yukihiro, Mizuno Kiyomichi, Yasuura Yoshiyuki, Kojima Hideaki, Ohde Yasuhisa
Division of General Thoracic Surgery, Shizuoka Cancer Center, Nagaizumicho Shimonagakubo 1007, Shizuoka, 411-8777, Japan.
Gen Thorac Cardiovasc Surg. 2019 Jun;67(6):544-550. doi: 10.1007/s11748-018-01059-2. Epub 2019 Jan 9.
The indication of limited resection for radiographically pure-solid, small-sized lung adenocarcinoma is controversial. This study aimed to reveal the long-term outcome of standard surgical treatment and determine the predictive factors for pathological lymph node metastasis in optimal candidates undergoing limited surgical resection for pure-solid, small-sized lung adenocarcinoma.
The medical records of 107 consecutive patients were retrospectively reviewed at our hospital between December 2002 and December 2013. Inclusion criteria were histopathological diagnosis of lung adenocarcinoma, radiographically pure-solid tumor, ≤ 2 cm tumor size measured using thin-section computed tomography, clinical N0M0, patients who underwent lobectomy with systematic or lobe-specific lymph node dissection, and R0 resection. Overall and disease-free survival curves were calculated using the Kaplan-Meier method. Clinicopathological factors predicting pathological node-positive metastasis were identified by univariate and multivariate analysis.
The 5-year overall and disease-free survival rates were 91.4% and 87.3%, respectively. Multivariate analysis demonstrated maximum standardized uptake value > 5 as the independent predictor of pathological node-positive metastasis (odds ratio 3.81; 95% confidence interval 1.25-12.3; p = 0.02). In all patients, the pathological node-positive rate was 16.7%; in patients who had a maximum standardized uptake value of ≤ 5, the rate was 7.9%.
The long-term outcome of standard surgical treatment was favorable. Maximum standardized uptake value was a significant predictor of pathological node-positive metastasis; however, diagnostic accuracy was not favorable. Therefore, the selection of optimal candidates is difficult, and limited surgical resection may not be applicable in pure-solid, small-sized lung adenocarcinoma.
对于影像学表现为纯实性、小尺寸肺腺癌行有限切除的指征存在争议。本研究旨在揭示标准手术治疗的长期结果,并确定接受纯实性、小尺寸肺腺癌有限手术切除的最佳候选者发生病理性淋巴结转移的预测因素。
回顾性分析2002年12月至2013年12月期间我院连续收治的107例患者的病历。纳入标准包括肺腺癌的组织病理学诊断、影像学表现为纯实性肿瘤、使用薄层计算机断层扫描测量肿瘤大小≤2 cm、临床N0M0、接受叶切除并进行系统性或叶特异性淋巴结清扫以及R0切除的患者。采用Kaplan-Meier法计算总生存曲线和无病生存曲线。通过单因素和多因素分析确定预测病理性淋巴结阳性转移的临床病理因素。
5年总生存率和无病生存率分别为91.4%和87.3%。多因素分析显示最大标准化摄取值>5是病理性淋巴结阳性转移的独立预测因素(比值比3.81;95%置信区间1.25-12.3;p=0.02)。所有患者的病理性淋巴结阳性率为16.7%;最大标准化摄取值≤5的患者,该率为7.9%。
标准手术治疗的长期结果良好。最大标准化摄取值是病理性淋巴结阳性转移的重要预测因素;然而,诊断准确性欠佳。因此,选择最佳候选者困难,有限手术切除可能不适用于纯实性、小尺寸肺腺癌。